Osteogenesis Imperfecta clinical trials

Explore recruiting osteogenesis imperfecta clinical trials.

Recruiting osteogenesis imperfecta studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Osteogenesis Imperfecta trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)

Netherlands, France, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Open-Label, Multicenter, Randomized Study to evaluate the Efficacy and Safety of Romosozumab Compared with Bisphophonates in Children and Adolecents with Osteogenesis Imperfecta

Slovakia, Germany, Belgium, Spain, Hungary, Austria +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multicenter, Safety Follow-up Study to Assess Safety of Prior Treatment with Romosozumab in Children and Adolescents with Osteogenesis Imperfecta

Germany, Hungary, Italy, Belgium, Austria, Slovakia +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid

France, Ireland, Netherlands, Denmark

Therapeutic use (Phase IV) EU CTIS Study details

An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Types I, III or IV

Netherlands, Germany, Italy, Poland, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Matrix-Directed Therapy In Older Adolescents And Adults With Osteogenesis Imperfecta – The “MOI-A” Study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Osteogenesis Imperfecta trials by city

Osteogenesis Imperfecta clinical trials

Recruiting osteogenesis imperfecta studies right now

Effects of Bisphosphonates on OI-Related Hearing Loss

Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta

Evaluation of Collagen-based Medical Device Treatment Combined With Physiotherapy in Subjects With Achilles Tendinopathy.

A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)

REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)

Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Osteogenesis Imperfecta

An Interventional Study to Evaluate the Impact of Blood Flow Restriction Training on Muscle, Bone, and Quality of Life in Adults With Osteogenesis Imperfecta Type I

Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

Also recruiting in Europe

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)

A Phase 3, Open-Label, Multicenter, Randomized Study to evaluate the Efficacy and Safety of Romosozumab Compared with Bisphophonates in Children and Adolecents with Osteogenesis Imperfecta

Multicenter, Safety Follow-up Study to Assess Safety of Prior Treatment with Romosozumab in Children and Adolescents with Osteogenesis Imperfecta

Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid

An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Types I, III or IV

Matrix-Directed Therapy In Older Adolescents And Adults With Osteogenesis Imperfecta – The “MOI-A” Study

Osteogenesis Imperfecta trials by city

Other conditions